In recent years, a better understanding of the biology and molecular pathology of multiple myeloma (MM) has resulted in significant therapeutic milestones. As the treatment of the disease continues to evolve, so do costs, prompting healthcare stakeholders to increasingly seek a value-based approach to patient management. The goal of this newsletter series, published by the Association for Value-Based Cancer Care®, is to report on the latest clinical updates pertaining to the treatment of myeloma and provide stakeholder perspectives on how these data can be used to promote high-quality, cost-effective care. Each supplement will answer a specific question that should be addressed when developing value-based care for patients with MM. In this first newsletter, we will explore whether therapeutic decisions can be made based on cytogenetic findings.